TOKYO (Reuters) – Takeda Pharmaceutical Co said on Wednesday the first subject had been given Novavax Inc’s COVID-19 vaccine candidate in a Japanese clinical trial.
Takeda has been contracted to handle the regulatory approvals for the vaccine in Japan. It will also manufacture and distribute up to 250 million doses of the vaccine candidate.
(Reporting by Rocky Swift; Editing by Himani Sarkar)
